Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Gut Pathogens
Published in: Gut Pathogens 1/2010

Open Access 01-12-2010 | Letter to the Editor

Compatible solutes: the key to Listeria's success as a versatile gastrointestinal pathogen?

Authors: Roy D Sleator, Colin Hill

Published in: Gut Pathogens | Issue 1/2010

Login to get access

Abstract

Recently we reported a role for compatible solute uptake in mediating bile tolerance and increased gastrointestinal persistence in the foodborne pathogen Listeria monocytogenes[1]. Herein, we review the evolution in our understanding of how these low molecular weight molecules contribute to growth and survival of the pathogen both inside and outside the body, and how this stress survival mechanism may ultimately be used to target and kill the pathogen.
Appendix
Available only for authorised users
Literature
1.
Watson D, Sleator RD, Casey PG, Hill C, Gahan CG: Specific osmolyte transporters mediate bile tolerance in Listeria monocytogenes. Infect Immun. 2009, 77: 4895-4904. 10.1128/IAI.00153-09.PubMedCentralCrossRefPubMed
2.
Sleator RD, Watson D, Hill C, Gahan CG: The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology. 2009, 155: 2463-2475. 10.1099/mic.0.030205-0.CrossRefPubMed
3.
Sleator RD, Hill C: A novel role for the LisRK two-component regulatory system in listerial osmotolerance. Clin Microbiol Infect. 2005, 11: 599-601. 10.1111/j.1469-0691.2005.01176.x.CrossRefPubMed
4.
Gray MJ, Freitag NE, Boor KJ: How the bacterial pathogen Listeria monocytogenes mediates the switch from environmental Dr. Jekyll to pathogenic Mr. Hyde. Infect Immun. 2006, 74: 2505-2512. 10.1128/IAI.74.5.2505-2512.2006.PubMedCentralCrossRefPubMed
5.
Freitag NE, Port GC, Miner MD: Listeria monocytogenes - from saprophyte to intracellular pathogen. Nat Rev Microbiol. 2009, 7: 623-628. 10.1038/nrmicro2171.PubMedCentralCrossRefPubMed
6.
Sleator RD, Francis GA, O'Beirne D, Gahan CG, Hill C: Betaine and carnitine uptake systems in Listeria monocytogenes affect growth and survival in foods and during infection. J Appl Microbiol. 2003, 95: 839-846. 10.1046/j.1365-2672.2003.02056.x.CrossRefPubMed
7.
Sleator RD, Wood JM, Hill C: Transcriptional regulation and posttranslational activity of the betaine transporter BetL in Listeria monocytogenes are controlled by environmental salinity. J Bacteriol. 2003, 185: 7140-7144. 10.1128/JB.185.24.7140-7144.2003.PubMedCentralCrossRefPubMed
8.
Sleator RD, Gahan CG, Hill C: A postgenomic appraisal of osmotolerance in Listeria monocytogenes. Appl Environ Microbiol. 2003, 69: 1-9. 10.1128/AEM.69.1.1-9.2003.PubMedCentralCrossRefPubMed
9.
Wemekamp-Kamphuis HH, Wouters JA, Sleator RD, Gahan CG, Hill C, Abee T: Multiple deletions of the osmolyte transporters BetL, Gbu, and OpuC of Listeria monocytogenes affect virulence and growth at high osmolarity. Appl Environ Microbiol. 2002, 68: 4710-4716. 10.1128/AEM.68.10.4710-4716.2002.PubMedCentralCrossRefPubMed
10.
Sleator RD, Gahan CG, Hill C: Identification and disruption of the proBA locus in Listeria monocytogenes: role of proline biosynthesis in salt tolerance and murine infection. Appl Environ Microbiol. 2001, 67: 2571-2577. 10.1128/AEM.67.6.2571-2577.2001.PubMedCentralCrossRefPubMed
11.
Sleator RD, Gahan CG, Hill C: Mutations in the listerial proB gene leading to proline overproduction: effects on salt tolerance and murine infection. Appl Environ Microbiol. 2001, 67: 4560-4565. 10.1128/AEM.67.10.4560-4565.2001.PubMedCentralCrossRefPubMed
12.
Sleator RD, Hill C: Bacterial osmoadaptation: the role of osmolytes in bacterial stress and virulence. FEMS Microbiol Rev. 2002, 26: 49-71. 10.1111/j.1574-6976.2002.tb00598.x.CrossRefPubMed
13.
Sleator RD, Gahan CGM, O'Driscoll B, Hill C: Analysis of the role of betL in contributing to the growth and survival of Listeria monocytogenes LO28. Int J Food Microbiol. 2000, 60: 261-268. 10.1016/S0168-1605(00)00316-0.CrossRefPubMed
14.
Sleator RD, Gahan CG, Abee T, Hill C: Identification and disruption of BetL, a secondary glycine betaine transport system linked to the salt tolerance of Listeria monocytogenes LO28. Appl Environ Microbiol. 1999, 65: 2078-2083.PubMedCentralPubMed
15.
Sleator RD, Wouters J, Gahan CG, Abee T, Hill C: Analysis of the role of OpuC, an osmolyte transport system, in salt tolerance and virulence potential of Listeria monocytogenes. Appl Environ Microbiol. 2001, 67: 2692-2698. 10.1128/AEM.67.6.2692-2698.2001.PubMedCentralCrossRefPubMed
16.
Obis D, Guillot A, Gripon JC, Renault P, Bolotin A, Mistou MY: Genetic and biochemical characterization of a high-affinity betaine uptake system (BusA) in Lactococcus lactis reveals a new functional organization within bacterial ABC transporters. J Bacteriol. 1999, 181: 6238-6246.PubMedCentralPubMed
17.
Dreux N, Albagnac C, Sleator RD, Hill C, Carlin F, Morris CE, Nguyen-the C: Glycine betaine improves Listeria monocytogenes tolerance to desiccation on parsley leaves independent of the osmolyte transporters BetL, Gbu and OpuC. J Appl Microbiol. 2008, 104: 1221-1227. 10.1111/j.1365-2672.2007.03623.x.CrossRefPubMed
18.
Wemekamp-Kamphuis HH, Sleator RD, Wouters JA, Hill C, Abee T: Molecular and physiological analysis of the role of osmolyte transporters BetL, Gbu, and OpuC in growth of Listeria monocytogenes at low temperatures. Appl Environ Microbiol. 2004, 70: 2912-2918. 10.1128/AEM.70.5.2912-2918.2004.PubMedCentralCrossRefPubMed
19.
Smiddy M, Sleator RD, Patterson MF, Hill C, Kelly AL: Role for compatible solutes glycine betaine and L-carnitine in listerial barotolerance. Appl Environ Microbiol. 2004, 70: 7555-7557. 10.1128/AEM.70.12.7555-7557.2004.PubMedCentralCrossRefPubMed
20.
Sheehan VM, Sleator RD, Hill C, Fitzgerald GF: Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology. 2007, 153: 3563-3571. 10.1099/mic.0.2007/006510-0.CrossRefPubMed
21.
Sleator RD, Wemekamp-Kamphuis HH, Gahan CG, Abee T, Hill C: A PrfA-regulated bile exclusion system (BilE) is a novel virulence factor in Listeria monocytogenes. Mol Microbiol. 2005, 55: 1183-1195. 10.1111/j.1365-2958.2004.04454.x.CrossRefPubMed
22.
Begley M, Sleator RD, Gahan CG, Hill C: Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect Immun. 2005, 73: 894-904. 10.1128/IAI.73.2.894-904.2005.PubMedCentralCrossRefPubMed
23.
Sleator RD, Banville N, Hill C: Carnitine enhances the growth of Listeria monocytogenes in infant formula at 7 degrees C. J Food Prot. 2009, 72: 1293-1295.PubMed
24.
Sleator RD, Hill C: Patho-biotechnology: using bad bugs to do good things. Curr Opin Biotechnol. 2006, 17: 211-216.CrossRefPubMed
25.
Sleator RD, Hill C: Patho-biotechnology; using bad bugs to make good bugs better. Sci Prog. 2007, 90: 1-14. 10.3184/003685007780440530.CrossRefPubMed
26.
Sleator RD, Hill C: Battle of the bugs. Science. 2008, 321: 1294-1295. 10.1126/science.321.5894.1294b.CrossRefPubMed
27.
Sleator RD, Hill C: Engineered pharmabiotics with improved therapeutic potential. Hum Vaccin. 2008, 4: 271-274.CrossRefPubMed
28.
Sleator RD, Hill C: Designer probiotics: a potential therapeutic for Clostridium difficile?. J Med Microbiol. 2008, 57: 793-794. 10.1099/jmm.0.47697-0.CrossRefPubMed
29.
Sleator RD, Hill C: 'Bioengineered Bugs' - a patho-biotechnology approach to probiotic research and applications. Med Hypotheses. 2008, 70: 167-169. 10.1016/j.mehy.2007.03.008.CrossRefPubMed
30.
Culligan EP, Hill C, Sleator RD: Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009, 1: 19-10.1186/1757-4749-1-19.PubMedCentralCrossRefPubMed
Metadata
Title
Compatible solutes: the key to Listeria's success as a versatile gastrointestinal pathogen?
Authors
Roy D Sleator
Colin Hill
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2010
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/1757-4749-2-20

Other articles of this Issue 1/2010

Gut Pathogens 1/2010 Go to the issue

Review

Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes

Research

Emerging trends in the etiology of enteric pathogens as evidenced from an active surveillance of hospitalized diarrhoeal patients in Kolkata, India

Review

Current insights in to the pathophysiology of Irritable Bowel Syndrome

Research

PFGE, Lior serotype, and antimicrobial resistance patterns among Campylobacter jejuni isolated from travelers and US military personnel with acute diarrhea in Thailand, 1998-2003

Research

Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells

Research

Isolation and detection of Mycobacterium avium subsp. paratuberculosis (MAP) from cattle in Ireland using both traditional culture and molecular based methods
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits